A device and method for preparing injectable autologous i-PRF
By designing a device for preparing injection-type autologous i-PRF, the problems of immature fibrin reticular structure and imbalance in PRF preparation are solved, and the extraction of liquid i-PRF is achieved, and the scope of clinical application is expanded. And reduces the risk of blood contamination and surgical area trauma.
Patent Information
- Application Number
- CN202011331118.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2020-11-24
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2040-11-24
AI Technical Summary
The existing PRF preparation methods have problems such as immature fibrin reticular structure, imbalance in cytokine release and limited clinical application, and there is a risk of blood contamination.
Design a device for the preparation of injection-type autologous i-PRF, including a barrel-shaped centrifuge tube that can be placed in a centrifuge, equipped with a protective cover, piercable membrane and slider, to extract liquid i through low-speed centrifugation and sterile operation -PRF, avoid external bacterial contamination and immune rejection risks.
It realizes control of fibrin agglutination rate, retention of growth factors and leukocytes, promotes tissue healing, expands the scope of clinical application, reduces costs, and reduces trauma in the surgical area.
Smart Images

Figure CN112371198B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to a device and a method for preparing injectable autologous i-PRF. Background Art
[0002] Autologous platelet-rich plasma (PRP) was first proposed in the 1970s and began to be widely used in the 1980s. Due to the addition of anticoagulant components that can cause immune rejection and is not easy to operate, in order to continue the advantages of PRP and avoid the above-mentioned shortcomings, Choukroun prepared the second-generation platelet concentrate in France in 2001, called platelet-rich fibrin (PRF). It is a fibrin clot rich in high-concentration platelets obtained by centrifuging autologous venous blood once without adding anticoagulants. From the ultrastructural point of view, it was found that the different conformations of the fibrin network structure are the main structural features that distinguish the two, and there are also obvious differences in density and type. The density of fibrin is determined by the amount of its raw material fibrinogen, and its type depends on the total amount of thrombin and the polymerization rate. In the preparation process of traditional PRP, unpolymerized fibrin will dissolve in PPP and be directly discarded. Therefore, when thrombin is added to promote blood coagulation, the fibrinogen content has been greatly reduced, making the density of the polymerized fibrin network structure much lower than the physiological blood clot. Due to the effect of exogenous additives, the high thrombin concentration makes the polymerization rate of fibrinogen much higher than the physiological reaction. The fibrin network formed is formed by the polymerization of four molecules of fibrinogen. It is rigid and lacks elasticity, which is not conducive to trapping cytokines and promoting cell migration. Therefore, the maturity of the fibrin network structure of PRF is better than that of PRP, which is closer to the physiological state. At the same time, the cytokine release pattern of PRF and traditional PRP products is also different. Due to the participation of exogenous additives, PRP products instantly activate the platelets in PRP, and the cytokines released after activation also have cytokines that accelerate platelet activation. Therefore, the release of its cytokines appears concentrated near the time of adding exogenous additives, that is, the early stage of the healing period after use, while the release in the later stage is less, and the release of cytokines is not balanced and lasting. In clinical application areas such as cartilage repair, tendon repair, and bone tissue repair, due to their long treatment and recovery cycles, continuous release of growth factors will more effectively promote tissue repair. Due to the structural advantages of PRF, cytokines can be released relatively persistently, which can better meet the needs of different clinical applications.
[0003] In recent years, many studies have shown that PRF can promote soft tissue repair and regeneration, and PRF has also begun to be used as a supplement for tissue regeneration. However, the PRF currently prepared is mainly in the form of fiber clots, which is not conducive to combining with other biomaterials, limiting its clinical application, and there is also the problem of blood contamination during the preparation process. Summary of the invention
[0004] In view of the existing deficiencies, the present invention provides a device and a method for preparing injectable autologous i-PRF.
[0005] The technical solution adopted by the present invention to solve its technical problems is: a device for preparing injectable autologous i-PRF, comprising a barrel-shaped centrifuge tube that can be placed in a centrifuge for centrifugation, the tube mouth of the centrifuge tube is sealed and connected with a protective cover that allows the injection needle to pass through, the protective cover is a cover with an insertion hole in the center or a protective film that can be pierced by the injection needle, and the aperture of the insertion hole matches the tube diameter of the injection needle; an axial opening is axially arranged on the side wall of the centrifuge tube, and a puncturable membrane that can be pierced and is used to close the axial opening is sealed and connected at the axial opening; a slider that slides in the axial opening is also slidably arranged on the side wall of the centrifuge tube, and a through hole corresponding to the axial opening is arranged on the slider; the puncturable membrane is sealed and connected to the end of the axial opening and is flush with the inner wall of the centrifuge tube, and the slider is slidably arranged in the axial opening close to the puncturable membrane.
[0006] Preferably, the protective film and the puncturable film are integrally formed and sealed to the side wall of the centrifuge tube.
[0007] Preferably, the slider is further provided with an injection hole communicated with the through hole, and a multi-way valve with multiple passages is installed in the through hole.
[0008] Preferably, the slider is detachably connected with a hollow internal piercing member that can be inserted into the through hole, and the piercing member is sealed with a collecting container that can communicate with the hollow portion thereof and can absorb liquid in the centrifuge tube.
[0009] A method for preparing injectable autologous i-PRF, using the device for preparing i-PRF described in any of the above, the specific steps are as follows:
[0010] S1, collect autologous blood and inject the collected blood into a centrifuge tube;
[0011] S2, placing the centrifuge tube into the centrifuge, balancing it, and centrifuging it at a low speed to separate the blood into a PRF layer and a red blood cell layer;
[0012] S3, after centrifugation is completed, the centrifuge tube is taken out, and the slider is slid so that the through hole on the slider is aligned with the junction of the PRF layer and the red blood cell layer or 1-1.5 mm below the junction;
[0013] S4, using a puncture needle to pierce the punctureable membrane through the through hole and insert into the blood, extracting the PRF layer into a collection container;
[0014] S5, shaking the PRF in the collection container to obtain i-PRF.
[0015] Preferably, the low-speed centrifugation is carried out at room temperature of 20-25°C, a centrifugal force of 40-60g, and a centrifugation time of no more than 5 minutes.
[0016] Preferably, the puncture needle is inserted to a depth of 0.8-1.5 cm.
[0017] The beneficial effects of the present invention are:
[0018] 1. The device of the invention has a simple structure and is easy to use. It reduces the risk of blood contacting bacteria and the probability of blood contamination during use;
[0019] 2. During the preparation process, except for the process of puncturing the membrane, which may bring in external bacteria, the blood will not come into contact with bacteria in other processes. In addition, there is no need to add thrombin or anticoagulants, and there is no risk of immune rejection, making the extracted i-PRF safer and more effective;
[0020] 3. The low-speed centrifugation method is used to slow down the aggregation rate of fibrin, so that autologous i-PRF can be prepared. At the same time, more growth factors and white blood cells are retained in PRF, which is more conducive to tissue healing. In addition, these growth factors can be slowly released to play a role, thereby better promoting tissue regeneration.
[0021] 4. The i-PRF prepared by the invention is a liquid with fluidity, which can be used alone or mixed with other biomaterials, expanding its scope of clinical application and solving the problem that the PRF prepared by traditional devices and methods is in the form of fiber gel, which is not conducive to combining with other biomaterials; it is also conducive to promoting tissue healing and regeneration and is easy to use and operate. The centrifugal extraction process and mixing process of the device of the present invention are simple to operate;
[0022] 5. Low cost. The platelet-rich fibrin in the present invention is obtained by centrifuging the patient's own blood, which significantly reduces the cost;
[0023] 6. The i-PRF produced by the invention is in liquid form, which can reduce trauma to the surgical area when used, thereby alleviating the patient's pain. BRIEF DESCRIPTION OF THE DRAWINGS
[0024] Figure 1 is a schematic structural diagram of an embodiment of the present invention;
[0025] Figure 2Embodiment of the present invention Figure 1 A is a schematic diagram of the enlarged structure of the middle part;
[0026] Figure 3 is a schematic diagram of the combined structure of the puncture member and the collection container according to an embodiment of the present invention;
[0027] Figure 4 is the amount of TGF-β released at each detection point in i-PRF and PRP in the embodiment of the present invention;
[0028] Figure 5 is the amount of IGF released at each detection point in i-PRF and PRP in the embodiment of the present invention;
[0029] Names and serial numbers of parts in the figure: 1-centrifuge tube 10-axial opening 11-puncturable membrane 2-protective cover 20-insertion through hole 3-slider 30-through hole 31-injection hole 4-puncture member 5-collection container. DETAILED DESCRIPTION
[0030] In order to more clearly illustrate the purpose, technical solutions and advantages of the embodiments of the present invention, the present invention will be further described in conjunction with the embodiments below, and a clear and complete description will be given. Obviously, the described embodiments are partial embodiments of the present invention, rather than all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work belong to the protection scope of the present invention. In addition, the directional terms mentioned in the present invention, such as "up", "down", "front", "back", "left", "right", "inside", "outside", etc., are only referenced to the directions of the attached diagrams. The directional terms used are for better and clearer explanation and understanding of the present invention, rather than indicating or implying the orientation that the present invention must have, and therefore cannot be understood as limitations on the present invention.
[0031] The embodiment of the present invention, as Figures 1 to 3As shown in the figure, a device for preparing injectable autologous i-PRF includes a centrifuge tube 1 of a barrel-shaped structure that can be placed in a centrifuge for centrifugation, that is, one end of the centrifuge tube 1 is open and the other end is closed, and the middle is a hollow accommodating cavity for holding the collected autologous blood. The tube mouth of the centrifuge tube 1 is sealed and connected with a protective cover 2 that allows the injection needle to pass through. The tube mouth is sealed and connected to the protective cover 2 so that the centrifuge tube 1 will not spill blood during the centrifugation process and also avoids the contact between blood and air. In order to enable the blood to be injected into the centrifuge tube 1, the protective cover 2 needs to be able to be penetrated by the injection needle. In actual application, a syringe and a blood collection needle are first used for autologous blood collection, and blood is collected into the syringe. Then, the blood collection needle is removed and replaced with a sterile injection needle connected to the syringe. Then, the injection needle passes through the protective cover 2, and the collected non-anticoagulated venous blood is injected into the centrifuge tube 1 along the inner wall of the centrifuge tube 1. The amount of blood collected is collected according to different situations, and the collection amount is preferably 0-10ml.At this time, for the protective cover 2, one way is that the protective cover 2 is a cover with an insertion hole 20 in the center, and the aperture of the insertion hole 20 matches the diameter of the injection needle. In this way, the protective cover 2 is sealed and connected to the tube mouth of the centrifuge tube 1. When blood is injected into the centrifuge tube 1, the injection needle is inserted into the insertion hole 20 set in the center of the protective cover 2, and the head of the injection needle is inserted into the centrifuge tube 1, so that the blood can be easily injected into the centrifuge tube 1. At the same time, since the aperture of the insertion hole 20 matches the diameter of the injection needle, it means that its aperture is relatively small and will not affect the centrifugation of the blood; another way is to use the protective cover 2 in a sealed manner. The protective cover 2 is a protective film that can be pierced by an injection needle. The protective film is made of a rubber composite film. During production, it can be sealed and connected to the mouth of the centrifuge tube 1 by thermoplastic packaging, which simplifies the structure and is more convenient to use. During use, the injection needle can pierce the protective film. At the same time, these two methods can also be used in combination. When used in combination, the protective film is first sealed and connected to the centrifuge tube 1, and then a cover with an insertion hole 20 is installed on the protective film. An axial opening 10 is axially arranged on the side wall of the centrifuge tube 1, that is, the axial opening 10 extends from the mouth of the centrifuge tube to the bottom of the tube, and is sealed at the axial opening 10. A puncturable membrane 11 which can be pierced and is used to close the axial opening 10 is connected. The puncturable membrane 11 closes the axial opening 10, so that the centrifuge tube 1 is still a tube body with a hollow barrel structure inside, and can still be used to hold blood. The fact that it can be pierced facilitates the extraction of PRF after blood stratification. The puncturable membrane 11 can also be made of a rubber composite membrane and is also sealed and connected to the centrifuge tube 1 by thermoplastic packaging. When the protective cover 2 is a protective film, the protective film and the puncturable membrane 11 can be integrally formed and sealed and connected to the side wall of the centrifuge tube 1, further simplifying the structure of the product and better reducing the cost. The side wall of the centrifuge tube 1 is also provided with a slider 3 that slides in the axial opening 10. The slider 3 is provided with a through hole 30 corresponding to the axial opening 10. The sliding of the slider 3 in the axial opening 10 enables it to be at different heights of the centrifuge tube 1. Its sliding is achieved through the slide rails and slide grooves that cooperate with each other. The slide rails and slide grooves are correspondingly arranged on the centrifuge tube 1 and the slider 3. If the slide groove is arranged on the centrifuge tube 1, then the slider 3 is provided with a slide rail. On the contrary, if the slide rail is arranged on the centrifuge tube 1, then the slider 3 is provided with a slide groove. The through hole 30 corresponds to the axial opening 10, which is conducive to the puncture of the puncturable membrane 11 during use. Such a device has a simple structure and is easy to use. It can effectively reduce the risk of blood contacting bacteria during use, thereby reducing the probability of blood being contaminated.
[0032] As a further improvement, the punctureable membrane 11 is sealed and connected to the end of the axial opening 10 and is flush with the inner wall of the centrifuge tube 1, that is, the punctureable membrane 11 is arranged on the side of the axial opening 10 located on the inner wall of the centrifuge tube 1, and is flush with the inner wall of the centrifuge tube 1, which means that there will be no seam between the punctureable membrane 11 and the inner wall of the centrifuge tube 1, and it will not affect the centrifugation of blood, and the PRF layer and the red blood cell layer can be better separated. The slider 3 is slidably arranged in the axial opening 10 close to the punctureable membrane 11, so that the puncture component reduces the chance of contact with the external environment during the process of puncturing the punctureable membrane 11, thereby reducing the chance of blood being contaminated.
[0033] Further improvements such as Figure 1 and Figure 2 As shown in the figure, the slider 3 is also provided with an injection hole 31 which is connected to the through hole 30, and a multi-way valve (not marked) with multiple channels is installed in the through hole 30, so that other biological materials, such as collagen, hyaluronic acid, etc., can be injected through the injection hole 31, and then the collected PRF and other biological materials can be conveniently mixed together through the control of the multi-way valve.
[0034] As a further improvement, the slider 3 may be detachably connected to a hollow piercing member 4 that can be inserted into the through hole 30. Figure 3 As shown in the figure, the puncture member 4 is sealed and connected with a collection container 5 which can be connected with the hollow part thereof and can absorb the liquid in the centrifuge tube 1; in this way, after the blood is centrifuged through the centrifuge tube 1, the puncture member 4 can easily pass through the through hole 30 to pierce the punctureable membrane, so that the separated liquid PRF in the centrifuge tube 1 can flow out through the hollow part inside the puncture member 4. The puncture member 4 can be a puncture needle that we conventionally use, or a puncture structure with a puncture needle at the head, and a connection structure connected to the collection container 5 at the tail, such as a snap-fit structure. At this time, the collection container 5 can be a cylindrical structure, one end of which is connected and connected with the puncture member 4, and the other end is provided with a sliding member that slides inside it, such as a syringe that we conventionally use. The puncture member 4 can also be a puncture needle structure at both the head and the tail. The collection container 5 is a container with a vacuum inside and a part that can be pierced by the puncture member 4. After the puncture member 4 pierces it, due to the pressure difference between the inside and the outside of the collection container 5, the PRF after centrifugation in the centrifuge tube 1 can be sucked into the collection container 5.
[0035] A method for preparing injectable autologous i-PRF, using the device for preparing i-PRF described in any of the above, the specific steps are as follows:
[0036] S1, collect autologous blood and inject the collected blood into a centrifuge tube, first select a blood collection needle connected to a syringe, collect blood into the syringe, then remove the blood collection needle, replace it with a sterile injection needle connected to the syringe, and finally inject the blood into the centrifuge tube through the protective cover on the centrifuge tube through the injection needle;
[0037] S2, place the centrifuge tube into the centrifuge, balance it and centrifuge it at a low speed to separate the blood into a PRF layer and a red blood cell layer. After the blood is injected into the centrifuge tube, immediately place the centrifuge tube into the centrifuge for low-speed centrifugation. The low-speed centrifugation is carried out at room temperature of 20-25°C, a centrifugal force of 40-60g, and a centrifugation time of no more than 5 minutes. According to the centrifugal principle, excessive centrifugal force or excessive centrifugation time can easily cause the blood without additional anticoagulants to contact the tube wall of the centrifuge device and immediately start the endogenous coagulation system, eventually generating a gel-type PRF. During centrifugation, the red blood cells and a small amount of platelets at the bottom of the centrifuge tube will settle down first faster, while the platelets and white blood cells at the top will be dispersed in the upper PRF under the low-speed centrifugation condition. Under such centrifugal conditions, more platelets and white blood cells can be enriched in the upper PRF, which can better achieve the enrichment of white blood cells and platelets in the upper layer, which is more conducive to cartilage healing when applied to cartilage defects. The PRF prepared under these conditions became liquid within 15 minutes with good fluidity and a white blood cell count of (3-8)×10 3 / μl, platelet count is (200~800)×10 3 / μl, the overall average release of TGF-β and IGF, important growth factors that promote cartilage tissue regeneration, are 1500-5500pg / ml and 500-5500pg / ml respectively. Collection, centrifugation and use can be completed in a short time, making the application more convenient and safer.
[0038] S3, after the centrifugation is finished, the centrifuge tube is taken out, and the slider is slid so that the through hole on the slider is aligned with the junction of the PRF layer and the red blood cell layer or 1-1.5mm below the junction. By sliding the slider, the centrifuge tube can be parked at any height position, and the puncture needle can be used to pierce the punctureable membrane to absorb PRF. When the slider is aligned with the position about 1-1.5mm below, PRF can be extracted as completely as possible.
[0039] S4, using a puncture needle to pierce the punctureable membrane through the through hole and insert into the blood, extracting the PRF layer into a collection container, the puncture needle is inserted to a depth of 0.8-1.5 cm, which can facilitate stable aspiration, reduce disturbance, and avoid affecting the extraction result of PRF. The extraction is performed slowly and at a uniform speed. At the same time, the puncture depth is limited, which can avoid disturbance of the centrifugally layered PRF layer and red blood cell layer during extraction. The preferred puncture depth is about 1 cm, and the extracted PRF layer is collected in the corresponding collection container;
[0040] S5, shake the PRF in the collection container to obtain i-PRF. At this time, the volume of the extracted i-PRF is 1 / 10-1 / 2 of the blood collection volume. The obtained i-PRF can be used as a material for cartilage repair and can be prepared as needed.
[0041] Such i-PRF preparation method is simple, low-cost, and does not add any anticoagulants or biological factors. Its characteristics are closer to natural fibrin matrix materials, avoiding the risk of immune rejection, cross infection and coagulation dysfunction. The prepared i-PRF can be used alone or mixed with other biological materials (such as collagen, hyaluronic acid, etc.) in vitro and injected into the joint cavity to achieve the repair and regeneration of damaged tissues, such as cartilage, ligaments, bone tissue, etc. During cartilage repair, it has a stimulating effect on the vertical migration of cartilage precursor cells, and can secrete different types of proteins related to cartilage matrix. At the same time, it can also promote the differentiation of precursor cells to form a transparent cartilage matrix. No secondary surgery is required. i-PRF can be injected alone or mixed with other biological materials into the cartilage defect under knee arthroscopy, so that cartilage can be repaired and regenerated, which can reduce the trauma to the surgical area.
[0042] In the embodiment, 10 ml of human blood without anticoagulant is collected in a centrifuge tube, and then the centrifuge tube is immediately placed in a centrifuge and centrifuged at room temperature for 3 minutes under 60g conditions. After centrifugation, the slider is slid to 1.5 mm below the blood stratification interface, and the syringe is connected to the slider. The injection needle pierces the punctureable membrane on the centrifuge tube horizontally, and the penetration depth is about 1 cm. Then the upper orange-yellow PRF is collected, and the volume is about 5 ml. At this time, it can be extracted according to actual use requirements, such as high concentration extraction 0-3 ml; medium concentration extraction 3-4 ml; low concentration extraction 4-5 ml, gently shake and shake to obtain i-PRF. At the same time, the collected i-PRF was tested for the in vitro release of growth factors, proving that the i-PRF prepared by this method has a positive effect on promoting cartilage repair.
[0043] Take a small amount of i-PRF and test it according to the microscope counting method of white blood cell and platelet count in the "National Clinical Laboratory Operation Procedure" (4th edition). In addition, place the i-PRF in a 37°C constant temperature incubator to release growth factors into the culture medium, and detect the growth factor concentration at 15 minutes, 1 hour, 8 hours, 1 day, 3 days and 10 days. At each time point, take a small amount of sample and measure the concentration of two growth factors, TGF-β and IGF, according to the instructions of the ELISA kit. The test results are as follows:
[0044] (1) The white blood cell and platelet counts in i-PRF were: 4.2×10 3 / μl, 285×10 3 / μl; (2) The release amounts of growth factor TGF-β at each detection point were: 582, 1227, 2364, 2145, 1446, 387pg / ml;
[0045] (3) The release amounts of growth factor IGF at each detection point were 416, 437, 619, 671, 367, and 61 pg / ml, respectively.
[0046] In addition, collect 10 ml of human blood into a centrifuge tube with an anticoagulant, centrifuge at 123g for 7 minutes, discard the red blood cells in the lower layer, centrifuge again at 1107g for 10 minutes, aspirate about 3 / 4 of the upper clear liquid from top to bottom, discard it, and the remaining in the centrifuge tube is PRP.
[0047] Take a small amount of PRP and test it according to the microscope counting method of white blood cell and platelet count in the "National Clinical Laboratory Operation Procedure" (4th edition). In addition, place the PRP in a 37°C constant temperature incubator to release growth factors into the culture medium, and test the growth factor concentration at 15 minutes, 1 hour, 8 hours, 1 day, 3 days and 10 days. At each time point, take a small amount of sample and measure the concentration of two growth factors, TGF-β and IGF, according to the instructions of the ELISA kit. The test results are as follows:
[0048] (1) The white blood cell and platelet counts in PRP were: 3.9×10 3 / μl, 237×10 3 / μl; (2) The release amounts of growth factor TGF-β at each detection point were: 4231, 3340, 3314, 1772, 1213, 262pg / ml;
[0049] (3) The release amounts of growth factor IGF at each detection point are: 263, 49, 43, 26, 19, 23 pg / ml
[0050] Comparing the white blood cell and platelet concentrations of i-PRF and PRP, it can be seen that the corresponding values are close. Among them, platelets play an important role in tissue repair and coagulation, and play a role by releasing various growth factors through their activation. Therefore, it can be considered that the total ability of i-PRF and PRP to release growth factors is equivalent. In addition, white blood cells play a role in inflammatory response and infection control, and the white blood cell concentrations of i-PRF and PRP are also close. It can be considered that the two have basically the same anti-infection ability.
[0051] like Figure 4 and Figure 5As shown in the figure, the in vitro release pattern of the growth factor of PRP and the i-PRF prepared in this embodiment is shown. It can be seen that the growth factor release pattern of i-PRF is different from that of traditional PRP products. Due to the participation of exogenous additives, the platelets in the PRP are instantly activated in the PRP product, and the cytokines released after activation also have the effect of accelerating platelet activation. Therefore, the release of its cytokines appears concentrated near the time of adding exogenous additives, that is, in the early stage of the healing period after use, while the release in the later stage is less, and the release of cytokines is not balanced and lasting. Due to the structural advantages of PRF, cytokines can be released relatively lastingly, which meets the needs of different clinical applications to a greater extent.
[0052] It should be understood that those skilled in the art can make improvements or changes based on the above description, and all these improvements and changes should fall within the scope of protection of the appended claims of the present invention.
Claims
1. A method for preparing injectable autologous i-PRF, characterized in that The specific steps are as follows: S1, collect autologous blood and inject the collected blood into a centrifuge tube; the centrifuge tube is a barrel-shaped centrifuge tube that can be placed in a centrifuge for centrifugation, the tube mouth of the centrifuge tube is sealed with a protective cover that allows the injection needle to pass through, the protective cover is a cover with an insertion hole in the center or a protective film that can be pierced by the injection needle, and the aperture of the insertion hole matches the tube diameter of the injection needle; an axial opening is axially arranged on the side wall of the centrifuge tube, and a puncturable membrane that can be pierced and is used to close the axial opening is sealed and connected at the axial opening; a slider that slides in the axial opening is also slidably arranged on the side wall of the centrifuge tube, and a through hole corresponding to the axial opening is arranged on the slider; the puncturable membrane is sealed and connected to the end of the axial opening and is flush with the inner wall of the centrifuge tube, and the slider is slidably arranged in the axial opening close to the puncturable membrane; S2, placing the centrifuge tube into a centrifuge, balancing it, and performing low-speed centrifugation to separate the blood into a PRF layer and a red blood cell layer, wherein the low-speed centrifugation is performed at a room temperature of 20-25° C., a centrifugal force of 40-60 g, and a centrifugation time of no more than 5 min; S3, after centrifugation is completed, the centrifuge tube is taken out, and the slider is slid so that the through hole on the slider is aligned with the junction of the PRF layer and the red blood cell layer or 1-1.5 mm below the junction; S4, using a puncture needle to pierce the punctureable membrane through the through hole and insert into the blood, extracting the PRF layer into a collection container; S5, shaking the PRF in the collection container to obtain i-PRF.
2. The method for preparing injectable autologous i-PRF according to claim 1, characterized in that : The insertion depth of the puncture needle is 0.8-1.5cm.
3. The method for preparing injectable autologous i-PRF according to claim 1, characterized in that The protective film and the puncturable film are integrally formed and sealedly connected to the side wall of the centrifuge tube.
4. The method for preparing injectable autologous i-PRF according to claim 1, characterized in that The slider is also provided with an injection hole which is in communication with the through hole, and a multi-way valve with multiple passages is installed in the through hole.
5. The method for preparing injectable autologous i-PRF according to claim 1, characterized in that The slider is also detachably connected with a hollow internal piercing member that can be inserted into the through hole, and the piercing member is sealed with a collecting container that can communicate with the hollow portion and absorb the liquid in the centrifuge tube.
Citation Information
Patent Citations
Platelet-rich plasma preparation device
CN108654141A
Preparation method and device of autologous platelet-rich plasma for treating pressure injury
CN109364529A
Double-network structure composite hydrogel as well as preparation method and application thereof
CN110743038A
Matched disposable centrifuge tube and centrifuge device and PRP preparation method
CN111036421A
Antibody incubation ultrasonic oscillation centrifuge tube
CN209460268U
